20/20 Biolabs, Inc.
AIDX
$1.46
$0.096.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.71% | 55.94% | 33.90% | 33.90% | 6.78% |
| Total Depreciation and Amortization | -38.34% | -39.54% | -37.18% | -37.18% | -11.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | -40.45% | -85.71% | -59.22% | -59.22% | 244.13% |
| Change in Net Operating Assets | 2,293.16% | -24.30% | 14.95% | 14.95% | -86.30% |
| Cash from Operations | 4.62% | 33.77% | 30.92% | 30.92% | 47.52% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -100.00% | 85.71% | 85.71% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 257.09% | 535.63% | 153.28% | 153.28% | 484.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 72.12% | 124.05% | 44.78% | 44.78% | 59.83% |